Skip to main content

MDNA · Medicenna Therapeutics Corp. · Financials

0.4400 CAD +0.0400 (+10.00%) At close · Nov 6 Intraday price with Plus

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Net Income
-10.05M +55.5%
FY2023 Net Income FY2020–FY2023
Operating Cash Flow
-23.58M -54%
FY2022 Operating Cash Flow FY2020–FY2022

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2023 FY2022 FY2021 FY2020
CAD 9.3M 14.72M 10.87M 5.87M
CAD 7M 7.76M 6.53M 2.38M
CAD 5000 37K 40K 8000
CAD -10.05M -22.58M -17.29M -8.28M
CAD 0 0 0 0
CAD -10.05M -22.58M -17.29M -8.28M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Noncurrent lease liabilities 2022-03-31 CAD 0 20-F filed 2022-06-22
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.